Actively Recruiting
OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities
Led by Changi General Hospital · Updated on 2025-03-21
120
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
Sponsors
C
Changi General Hospital
Lead Sponsor
N
National University of Singapore
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adults with diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). Researchers will compare this model with the conventional standard of care of physical visit-based weight management program to see if this model is non-inferior to the standard of care for inducing weight loss, and if there is greater patient convenience with telehealth and more frequent self-monitoring, compliance with diet advice and exercise participation compared to standard of care. Participants in the standard arm will attend 4 physical doctor and 4 physical dietician consultations over 26 weeks, where they will be provided with an individualized diet and exercise prescription to induce at least 5% weight loss. Participants in the intervention arm will have the same number of consults over 26 weeks, of which at least 50% will be teleconsults, and will also be provided with an individualized diet and exercise prescription to induce at least 5% weight loss. In addition, they will be taught to use the EMPOWER app to upload weight, blood pressure and glucose, food and exercise records which will be reviewed at the consults. The app also delivers nudges to improve adherence to lifestyle modification.
CONDITIONS
Official Title
OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 21-70
- Body mass index > 27.5 kg/m2
- Waist circumference > 90 cm in men or 80 cm in women
- Suboptimal control of type 2 diabetes (HbA1c > 6.5%) AND/OR MASLD confirmed by liver imaging or biopsy
You will not qualify if you...
- Men who drink more than 21 units of alcohol per week or women who drink more than 14 units per week
- Previous use of weight-lowering medications without a minimum 3-month wash-out period
- Illness with life expectancy less than 6 months
- Inability to follow written instructions in English
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Changi General Hospital
Singapore, Singapore, 529889
Actively Recruiting
Research Team
J
Joan Khoo, MBBS, FRCP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here